Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

The economic burden of multidrug-resistant tuberculosis.

Caminero JA, Scardigli A.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):831-832. doi: 10.5588/ijtld.18.0408. No abstract available.

PMID:
29991388
2.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
3.

Low-dose amoxicillin-clavulanate in drug-resistant tuberculosis.

Mishra GP, Caminero JA.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):465. doi: 10.5588/ijtld.18.0055. No abstract available.

PMID:
29562998
4.

Comments on the SEPAR Guidelines for the Diagnosis and Treatment of Drug-Resistant Tuberculosis.

Caminero JA, Caylá JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J.

Arch Bronconeumol. 2018 May;54(5):298. doi: 10.1016/j.arbres.2017.12.015. Epub 2018 Feb 9. English, Spanish. No abstract available.

5.

Bedaquiline: how better to use it.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701670. doi: 10.1183/13993003.01670-2017. Print 2017 Nov. No abstract available.

PMID:
29122921
6.

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700648. doi: 10.1183/13993003.00648-2017. Print 2017 Jul. No abstract available.

PMID:
28679614
7.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

PMID:
28529205
8.

Diagnosis and Treatment of Drug-Resistant Tuberculosis.

Caminero JA, Cayla JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J.

Arch Bronconeumol. 2017 Sep;53(9):501-509. doi: 10.1016/j.arbres.2017.02.006. Epub 2017 Mar 27. English, Spanish.

9.

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Galesi VM, Barreira D, Sanchez DA, Dockhorn F, Centis R, Caminero JA, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602445. doi: 10.1183/13993003.02445-2016. Print 2017 Mar.

PMID:
28331044
10.

Tuberculosis drug resistance in Southern Mozambique: results of a population-level survey in the district of Manhiça.

Valencia S, Respeito D, Blanco S, Ribeiro RM, López-Varela E, Sequera VG, Saavedra B, Mambuque E, Morillo MG, Bulo H, Cobelens F, Macete E, Alonso PL, Caminero JA, García-Basteiro AL.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):446-451. doi: 10.5588/ijtld.16.0694.

PMID:
28284261
11.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383
12.

In reply.

Bollela VR, Caminero JA.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):124. doi: 10.5588/ijtld.16.0619-2. No abstract available.

PMID:
28157480
13.

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Rendon A, Tiberi S, Scardigli A, D'Ambrosio L, Centis R, Caminero JA, Migliori GB.

J Thorac Dis. 2016 Oct;8(10):2666-2671. No abstract available.

14.

[Tuberculosis in children. Challenges and opportunities].

Caminero JA, Scardigli A.

An Pediatr (Barc). 2016 Dec;85(6):281-283. doi: 10.1016/j.anpedi.2016.09.012. Epub 2016 Nov 4. Spanish. No abstract available.

15.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

16.

Simple and practical measures to reduce tuberculosis transmission in public buildings.

Scardigli A, Caminero JA.

Int J Tuberc Lung Dis. 2016 Sep;20(9):1137-8. doi: 10.5588/ijtld.16.0450. No abstract available.

PMID:
27510232
17.

Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment.

Rodrigo T, Casals M, Caminero JA, García-García JM, Jiménez-Fuentes MA, Medina JF, Millet JP, Ruiz-Manzano J, Caylá J; Working Group of the Integrated Programme of Tuberculosis Research.

PLoS One. 2016 Aug 3;11(8):e0159925. doi: 10.1371/journal.pone.0159925. eCollection 2016.

18.

Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.

Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1099-104. doi: 10.5588/ijtld.15.0864.

19.

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.

Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, Migliori GB.

Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23. No abstract available.

20.

Tuberculosis Costs in Spain and Related Factors.

Gullón JA, García-García JM, Villanueva MÁ, Álvarez-Navascues F, Rodrigo T, Casals M, Anibarro L, García-Clemente MM, Jiménez MÁ, Bustamante A, Penas A, Caminero JA, Caylà J; Grupo de Trabajo del Programa Integrado de Investigación en Tuberculosis (PII TB).

Arch Bronconeumol. 2016 Dec;52(12):583-589. doi: 10.1016/j.arbres.2016.05.002. Epub 2016 Jun 17. English, Spanish.

21.

Efficacy and tolerability of ethionamide versus prothionamide: a systematic review.

Scardigli A, Caminero JA, Sotgiu G, Centis R, D'Ambrosio L, Migliori GB.

Eur Respir J. 2016 Sep;48(3):946-52. doi: 10.1183/13993003.00438-2016. Epub 2016 Jun 10. Review. No abstract available.

22.

Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study.

Campos-Herrero MI, Chamizo FJ, Caminero JA, Gilarranz R, Cabrera G, Cuyás J.

J Infect Chemother. 2016 Aug;22(8):526-31. doi: 10.1016/j.jiac.2016.04.010. Epub 2016 Jun 1.

PMID:
27262751
23.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

24.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

25.

The changing landscape in drug resistant-tuberculosis: an analysis of recent advances.

Monedero I, Caminero JA, Bhavaraju R, Sanchez-Montalva A.

Expert Rev Respir Med. 2016 Jun;10(6):603-6. doi: 10.1586/17476348.2016.1164042. Epub 2016 Mar 28. No abstract available.

PMID:
26954921
26.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
27.

Classification of antituberculosis drugs: a new proposal based on the most recent evidence.

Caminero JA, Scardigli A.

Eur Respir J. 2015 Oct;46(4):887-93. doi: 10.1183/13993003.00432-2015. No abstract available.

28.

Automated Digital Microscopy in New Tuberculosis Diagnostic Algorithms. Can It Boost Case Finding?

Caminero JA, Migliori GB.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1352-3. doi: 10.1164/rccm.201504-0790ED. No abstract available.

PMID:
26075421
29.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET.

Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.

30.

Common errors in multidrug-resistant tuberculosis management.

Monedero I, Caminero JA.

Expert Rev Respir Med. 2014 Feb;8(1):15-23. doi: 10.1586/17476348.2014.856758. Epub 2013 Dec 16.

PMID:
24329041
31.

Tuberculosis: are we making it incurable?

Caminero JA, Matteelli A, Loddenkemper R.

Eur Respir J. 2013 Jul;42(1):5-8. doi: 10.1183/09031936.00206712. No abstract available.

32.

Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic.

Rodriguez M, Monedero I, Caminero JA, Encarnación M, Dominguez Y, Acosta I, Muñoz E, Camilo E, Martinez-Selmo S, de los Santos S, del Granado M, Casals M, Cayla J, Marcelino B.

Int J Tuberc Lung Dis. 2013 Apr;17(4):520-5. doi: 10.5588/ijtld.12.0481.

PMID:
23485386
33.

Management of multidrug resistant tuberculosis.

Daley CL, Caminero JA.

Semin Respir Crit Care Med. 2013 Feb;34(1):44-59. doi: 10.1055/s-0032-1333546. Epub 2013 Mar 4. Review.

PMID:
23460005
34.

High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: a public-private initiative.

Villegas SL, Ferro BE, Perez-Velez CM, Moreira CA, Forero L, Martínez E, Rastogi N, Caminero JA.

Eur Respir J. 2012 Dec;40(6):1569-72. doi: 10.1183/09031936.00018212. No abstract available.

35.

A predictive scoring instrument for tuberculosis lost to follow-up outcome.

Rodrigo T, Caylà JA, Casals M, García-García JM, Caminero JA, Ruiz-Manzano J, Blanquer R, Vidal R, Altet N, Calpe JL, Penas A; Working Group on Completion of Tuberculosis Treatment in Spain.

Respir Res. 2012 Sep 2;13:75. doi: 10.1186/1465-9921-13-75.

36.

Empirical use of fluoroquinolones for chest infections may mask tuberculosis and jeopardise chances of survival.

Leung CC, Caminero JA.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1137. doi: 10.5588/ijtld.12.0518. No abstract available.

PMID:
22871321
37.

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB.

Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10. Review.

38.

European union standards for tuberculosis care.

Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D.

Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811.

39.

Rapid test for identification of a highly transmissible Mycobacterium tuberculosis Beijing strain of sub-Saharan origin.

Millán-Lou MI, Alonso H, Gavín P, Hernández-Febles M, Campos-Herrero MI, Copado R, Cañas F, Kremer K, Caminero JA, Martín C, Samper S.

J Clin Microbiol. 2012 Feb;50(2):516-8. doi: 10.1128/JCM.06314-11. Epub 2011 Nov 23.

40.

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.

Singla R, Caminero JA, Jaiswal A, Singla N, Gupta S, Bali RK, Behera D.

Eur Respir J. 2012 Apr;39(4):956-62. doi: 10.1183/09031936.00076811. Epub 2011 Sep 29.

41.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.

42.

Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review.

Monedero I, Caminero JA.

Int J Tuberc Lung Dis. 2011 Apr;15(4):433-9. doi: 10.5588/ijtld.09.0439. Review.

PMID:
21396199
43.

Social, clinical and microbiological differential characteristics of tuberculosis among immigrants in Spain.

García-García JM, Blanquer R, Rodrigo T, Caylà JA, Caminero JA, Vidal R, Casals M, Ruiz-Manzano J; Working Group on Completion of Tuberculosis Treatment in Spain.

PLoS One. 2011 Jan 20;6(1):e16272. doi: 10.1371/journal.pone.0016272.

44.

Treatment of multidrug-resistant tuberculosis: definition of the outcome 'failure'.

Chiang CY, Van Deun A, Trébucq A, Heldal E, Caminero JA, Aït-Khaled N.

Int J Tuberc Lung Dis. 2011 Jan;15(1):4-5. No abstract available.

PMID:
21276289
45.

Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds.

Sologuren I, Boisson-Dupuis S, Pestano J, Vincent QB, Fernández-Pérez L, Chapgier A, Cárdenes M, Feinberg J, García-Laorden MI, Picard C, Santiago E, Kong X, Jannière L, Colino E, Herrera-Ramos E, Francés A, Navarrete C, Blanche S, Faria E, Remiszewski P, Cordeiro A, Freeman A, Holland S, Abarca K, Valerón-Lemaur M, Gonçalo-Marques J, Silveira L, García-Castellano JM, Caminero J, Pérez-Arellano JL, Bustamante J, Abel L, Casanova JL, Rodríguez-Gallego C.

Hum Mol Genet. 2011 Apr 15;20(8):1509-23. doi: 10.1093/hmg/ddr029. Epub 2011 Jan 25.

46.

Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237.

Alonso H, Aguilo JI, Samper S, Caminero JA, Campos-Herrero MI, Gicquel B, Brosch R, Martín C, Otal I.

Tuberculosis (Edinb). 2011 Mar;91(2):117-26. doi: 10.1016/j.tube.2010.12.007. Epub 2011 Jan 20.

PMID:
21256084
47.

Spontaneous pneumothorax and tuberculosis: long-term follow-up.

Freixinet JL, Caminero JA, Marchena J, Rodríguez PM, Casimiro JA, Hussein M.

Eur Respir J. 2011 Jul;38(1):126-31. doi: 10.1183/09031936.00128910. Epub 2010 Oct 14.

48.

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Caminero JA, Sotgiu G, Zumla A, Migliori GB.

Lancet Infect Dis. 2010 Sep;10(9):621-9. doi: 10.1016/S1473-3099(10)70139-0. Review.

PMID:
20797644
49.

MDR-/XDR-TB management: what it was, current standards and what is ahead.

Monedero I, Caminero JA.

Expert Rev Respir Med. 2009 Apr;3(2):133-45. doi: 10.1586/ers.09.6.

PMID:
20477307
50.

Management of multidrug-resistant tuberculosis: an update.

Monedero I, Caminero JA.

Ther Adv Respir Dis. 2010 Apr;4(2):117-27. doi: 10.1177/1753465810365884. Epub 2010 Apr 13. Review.

PMID:
20388724

Supplemental Content

Loading ...
Support Center